可治疗靶向的TAZ-TEAD2通路通过ANLN和KIF23驱动肝细胞癌生长
研究在小鼠肝细胞癌模型中考察肿瘤细胞表达的YAP和TAZ的调控与功能。发现TAZ缺失可降低肿瘤生长和死亡率,激活型TAZ过表达足以诱发肝癌,TAZ受胆固醇合成调控并通过TEAD2及靶基因ANLN、KIF23促进增殖;pan-TEAD抑制剂或他汀联合索拉非尼或抗PD-1可减缓肿瘤生长。
要点
- TAZ缺失一致降低小鼠肝细胞癌生长和死亡率,激活型TAZ过表达足以诱发肝癌。
- TAZ表达受胆固醇合成调控,TAZ/MET/CTNNB1-S45Y驱动肝癌需要TEAD2,TEAD4作用较小。
- TAZ和TEAD2通过靶基因ANLN和KIF23促进肿瘤细胞增殖。
核心结论
- 结果提示胆固醇-TAZ-TEAD2-ANLN/KIF23通路介导肝细胞癌增殖,是肿瘤细胞内在的治疗靶点,可与肿瘤免疫微环境靶向治疗协同联合。
研究设计与样本
- 小鼠肝细胞癌模型:通过Sleeping Beauty介导表达MET、CTNNB1-S45Y或TAZ-S89A,或二乙基亚硝胺加CCl4诱导肝癌。
- floxed小鼠通过腺相关病毒血清型8介导表达Cre删除肝细胞TAZ和YAP。
- TAZ靶基因通过RNA测序鉴定、染色质免疫沉淀确认,并在CRISPRi筛选中评估。
- 在dead Cas9敲入小鼠中用向导RNA敲低TEADs、ANLN、Kif23和程序性细胞死亡蛋白配体1。
主要发现
- YAP和TAZ在小鼠和人肝细胞癌中上调,但仅TAZ缺失一致降低肝细胞癌生长和死亡率。
- 激活型TAZ过表达足以触发肝细胞癌。
- 药理学或遗传学抑制HMGCR、法尼基焦磷酸合酶、FDFT1或SREBP2可调控TAZ表达。
- TAZ和MET/CTNNB1-S45Y驱动的肝细胞癌需要TEAD2表达,TEAD4作用较小。
- TEAD2对肝细胞癌患者生存影响最显著;TAZ和TEAD2通过ANLN和KIF23介导的肿瘤细胞增殖促进肝细胞癌。
关键数值与推荐
- 原文未报告具体推荐等级或阈值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite recent progress, long-term survival remains low for hepatocellular carcinoma (HCC). The most effective HCC therapies target the tumor immune microenvironment (TIME), and there are almost no therapies that directly target tumor cells. Here, we investigated the regulation and function of tumor cell-expressed Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in HCC. METHODS: HCC was induced in mice by Sleeping Beauty-mediated expression of MET, CTNNB1-S45Y, or TAZ-S89A, or by diethylnitrosamine plus CCl4. Hepatocellular TAZ and YAP were deleted in floxed mice via adeno-associated virus serotype 8-mediated expression of Cre. TAZ target genes were identified from RNA sequencing, confirmed by chromatin immunoprecipitation, and evaluated in a clustered regularly interspaced short palindromic repeats interference (CRISPRi) screen. TEA domain transcription factors (TEADs), anillin (ANLN), Kif23, and programmed cell death protein ligand 1 were knocked down by guide RNAs in dead clustered regularly interspaced short palindromic repeats-associated protein 9 (dCas9) knock-in mice. RESULTS: YAP and TAZ were up-regulated in murine and human HCC, but only deletion of TAZ consistently decreased HCC growth and mortality. Conversely, overexpression of activated TAZ was sufficient to trigger HCC. TAZ expression in HCC was regulated by cholesterol synthesis, as demonstrated by pharmacologic or genetic inhibition of 3-hydroxy-3-methylglutaryl- coenzyme A reductase (HMGCR), farnesyl pyrophosphate synthase, farnesyl-diphosphate farnesyltransferase 1 (FDFT1), or sterol regulatory element-binding protein 2 (SREBP2). TAZ- and MET/CTNNB1-S45Y-driven HCC required the expression of TEAD2 and, to a lesser extent, TEAD4. Accordingly, TEAD2 displayed the most profound effect on survival in patients with HCC. TAZ and TEAD2 promoted HCC via increased tumor cell proliferation, mediated by TAZ target genes ANLN and kinesin family member 23 (KIF23). Therapeutic targeting of HCC, using pan-TEAD inhibitors or the combination of a statin with sorafenib or anti-programmed cell death protein 1, decreased tumor growth. CONCLUSIONS: Our results suggest the cholesterol-TAZ-TEAD2-ANLN/KIF23 pathway as a mediator of HCC proliferation and tumor cell-intrinsic therapeutic target that could be synergistically combined with TIME-targeted therapies.
引用
- Saito Y, Yin D, Kubota N, et al. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology. 2023. PMID: 36894036. doi:10.1053/j.gastro.2023.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。